Epclusa Cost in Mexico: Why It Isn’t the Cheap Source — and How to Get It for $0

If you are searching for “Epclusa cost in Mexico,” you are almost certainly looking for one thing: a way to afford a cure. Epclusa (sofosbuvir/velpatasvir) cures nearly everyone with hepatitis C — a sustained virologic response in about 98 to 99 percent of patients across every genotype — but its US list price sits near $74,760 for a full course. The instinct to look south of the border is understandable. The honest answer, though, is that Mexico is not the low-cost source many people expect it to be, and SunnyPharma compiled this guide to explain why, and to show the US pathways that reliably bring the cost to $0.

This guide covers Epclusa’s verified US pricing, the reason Mexico sits outside the low-cost generic supply chain, what importing an India-licensed generic actually costs once it crosses a border, and every US assistance pathway worth exhausting before you consider traveling for treatment.

Why “Epclusa in Mexico” Is Not the Bargain It Sounds Like

The expectation behind a search for cheap Epclusa in Mexico is reasonable: many medicines do cost far less outside the United States. But for Epclusa specifically, that expectation rests on a false premise, and it is worth stating plainly before you make any plans.

When Gilead licensed manufacturers to produce low-cost generic sofosbuvir/velpatasvir, it did so through a voluntary-licensing program covering roughly 101 lower-income countries — with India as the main manufacturing hub. As documented in peer-reviewed analysis of Gilead’s licensing strategy, a number of middle-income countries were deliberately left out of that program — and Mexico is one of the excluded countries. The roughly $300 in-country generic price that exists in India is a direct product of that license. It does not exist in Mexico, because Mexico is not in the license.

SunnyPharma cannot verify Mexican pharmacy retail prices for Epclusa to a reliable standard — reported figures vary enormously and the lowest often come from unverified resellers rather than licensed pharmacies. Because Mexico is not a dependable low-cost source, we do not publish a headline Mexico price. A number we cannot stand behind would not serve you. The dependable route to $0 is the set of US pathways further down this page.

What Epclusa Actually Costs: US List, Authorized Generic, and the Import Reality

The table below summarizes the pricing reference points that can be verified for a standard 12-week Epclusa course. US figures are the manufacturer’s wholesale acquisition cost (WAC) or authorized-generic list price; the imported-generic figure reflects the real all-in cost of bringing a licensed India generic across a border, not its in-country shelf price.

Sources: Gilead price information (WAC Jan 1, 2026); peer-reviewed licensing analysis (PMC); reported current market pricing for imported generics, 2026. Figures approximate.

The India Generic: Why the Low Price Isn’t the Price You Pay

Because India is inside Gilead’s licensing program, a 12-week generic sofosbuvir/velpatasvir course is genuinely inexpensive there — reported around $300 in-country. That figure is real, and it is the number that drives a lot of cross-border searching. But it is the in-country pharmacy price, not what someone abroad pays to actually obtain the medicine.

A patient outside the licensed countries who imports a course typically pays closer to $800 to $1,000 all-in once export handling, customs and duties, international shipping, and facilitator fees are added on top of the pills themselves. Getting a prescription medicine legally out of one country and into another is not a simple online checkout — the logistics are a large part of the cost, and they are also where the risk lives.

Patient Assistance Pathways US Patients Should Exhaust First

Before considering treatment abroad — or any non-domestic source — most US patients have access to legitimate pathways that reduce Epclusa cost to $0. These programs exist precisely because hepatitis C treatment is both highly effective and expensive at list price.

1. Gilead Support Path: Copay Coupon and Patient Assistance Program

Gilead Sciences operates two distinct programs through Support Path:

Copay Coupon (commercially insured patients): reduces your cost to as little as $5 per month. It does not apply to Medicare, Medicaid, TRICARE, VA, or other government plans.

Patient Assistance Program (uninsured patients): provides Epclusa or its authorized generic at no cost to eligible uninsured patients who meet income criteria. Call 1-855-769-7284 or enroll online, or ask your hepatology clinic’s social work team to assist with the application.

2. Medicaid

As of 2026, most state Medicaid programs cover Epclusa or its authorized generic, and most Medicaid beneficiaries pay $0 for a full course. Some states eliminate copays entirely. Prior authorization rules vary by state; many states have removed historical access restrictions such as fibrosis-stage gates and sobriety requirements. If you are uninsured and may qualify based on income, applying is often the fastest path to coverage.

3. Medicare

Epclusa is covered by most Medicare Part D and Advantage plans. The 2025 Part D reform caps annual out-of-pocket spending at $2,000, and per Gilead about 80 percent of Medicare patients pay $15 or less per month. Manufacturer copay coupons cannot be used with Medicare, but patients with limited income can apply for Extra Help (the Low Income Subsidy), which can lower costs further, and Support Path can help navigate Medicare-specific options.

4. ADAP (HIV Co-Infection) and 340B Clinics

Patients co-infected with HIV and hepatitis C may qualify for Epclusa through state AIDS Drug Assistance Programs (ADAP) — this route is specifically for people living with HIV, not a general hepatitis C pathway. Separately, the 340B program lets eligible Federally Qualified Health Centers and other covered entities access Epclusa at substantially reduced prices. If you receive care at an FQHC or 340B-eligible facility, ask whether your prescription can benefit.

5. Nonprofit Copay Foundations

For Medicare patients (who cannot use manufacturer copay coupons) or insured patients facing high cost-sharing, several foundations periodically offer hepatitis C copay assistance:

• Patient Advocate Foundation (PAF) — copay relief and free case management for insurance denials.
• Patient Access Network (PAN) Foundation — grants for HCV treatment, copays, deductibles, and premiums.
• HealthWell Foundation — HCV fund for copay assistance when funding is available.
• NeedyMeds — aggregates assistance programs and free/low-cost clinic locations.

Epclusa Efficacy, Genotype Coverage, and Course Length

Epclusa (sofosbuvir 400mg / velpatasvir 100mg) is a once-daily, fixed-dose direct-acting antiviral that produces sustained virologic response (SVR) — the standard definition of a hepatitis C cure — in roughly 98 to 99 percent of patients across the ASTRAL clinical trial program. SVR sustained at 12 weeks post-treatment is generally considered a durable cure.

Pan-Genotypic Coverage

Unlike some older regimens, Epclusa is pan-genotypic — it treats all six major HCV genotypes (1, 2, 3, 4, 5, and 6) in adults and children aged 3 and older who weigh at least 17 kg, with or without compensated cirrhosis. This is a key clinical advantage: a single regimen works regardless of genotype, which is one reason physicians often choose it. For genotype-specific cost comparisons, see our full Epclusa USA cost guide.

One 12-Week Course

The standard Epclusa course is one tablet daily for 12 weeks (84 tablets). Children who cannot swallow tablets may use Epclusa oral pellets at weight-appropriate doses.

Legal Status of Personal-Use Importation

The FDA states that in most circumstances, it is illegal for individuals to import non-FDA-approved drugs into the United States. The agency maintains a discretionary enforcement policy that may not pursue action against small-quantity personal-use importation under certain conditions — but this is enforcement discretion, not a legal right, and it can be revised at any time.

Bringing prescription medication purchased at a Mexican pharmacy back across the US border is a separate question with its own customs considerations. CBP and FDA officers have discretion at the border, and seizure of medication is a possible outcome, particularly for quantities suggesting non-personal use. These regulatory realities are part of why the US assistance pathways above matter: they offer legal, supported, in-country routes to a cure that do not depend on enforcement discretion or an unverifiable foreign price.

Frequently Asked Questions